Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All ClaimsSettlement Agreement and Mutual Release of All Claims • September 5th, 2008 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and The Salk Institute for Biological Studies (SALK) have entered into a Settlement Agreement and Mutual Release of All Claims (Settlement Agreement). Through the Settlement Agreement, the parties have resolved all disputes that have arisen between them including SALK’s primary claim in arbitration relating to the sale of Targretin® to Eisai Inc. in 2006. In addition, the parties have agreed to jointly seek dismissal with prejudice of all claims and counterclaims asserted in the ongoing arbitration between the parties.
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All ClaimsSettlement Agreement and Mutual Release of All Claims • April 19th, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and The Salk Institute for Biological Studies (SALK) have entered into a Settlement Agreement and Mutual Release of All Claims (Settlement Agreement). Through the Settlement Agreement, the parties have resolved all disputes that have arisen between them including SALK's primary claim in arbitration
A PORTION OF THIS AGREEMENT HAS BEEN REDACTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IT WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Settlement Agreement and Mutual Release of All Claims • September 30th, 2020 • Ministry Partners Investment Company, LLC • Finance services • Minnesota
This Settlement Agreement and Mutual Release of All Claims ("Agreement") is entered into by and between OSK VII, LLC ("Lender"), as assignee of THE NATIONAL CREDIT UNION ADMINISTRATION BOARD AS LIQUIDATING AGENT OF WESTERN CORPORATE FEDERAL CREDIT UNION (“Seller”) and MINISTRY PARTNERS INVESTMENT COMPANY,
